FOXO4
10MGFOXO4-p53 interfering peptide, D-retro-inverso.
6 peer-reviewed citations for this compound
Read the sourcesVolume tiers count vials of this compound at this strength. Mixing different compounds does not combine toward a tier.
- ≥99% purity specification
- Secure checkout
- Ships in 1 business day
- Research use only
Released against a ≥99% HPLC purity specification and supplied as a sealed laboratory reagent for in vitro research use only.
- Type
- FOXO4-p53 interfering peptide (D-retro-inverso)
- Form
- Lyophilized powder
- Vial strength
- 10MG
- Purity specification
- ≥99% by HPLC
Identifiers are published properties of the molecule. Values we cannot confirm are omitted rather than estimated.
Dispatch
Ships within 1 business day of order confirmation, from the US. Vials ship lyophilized at ambient temperature; move them to the storage condition below on arrival.
Lyophilized
Store at -20°C, protected from light. Stable 24+ months sealed.
Reconstituted
Store at 2-8°C. Use within approximately 30 days.
How FOXO4 is described to act.
FOXO4-DRI is a retro-inverso, all-D-amino-acid peptide modelled on the FOXO4 region that contacts p53, fused to a cationic cell-permeability sequence. Solution NMR structural models show that the disordered peptide binds the disordered p53 transactivation domain (p53TAD2) to form a transiently folded complex, with both the FOXO4-derived region and the cell-permeability peptide contributing to the interaction, and with p53 phosphorylation increasing affinity for both FOXO4 and FOXO4-DRI. Senescent cells are reported to depend on a FOXO4-p53 interaction that retains p53 in the nucleus for their continued viability; the peptide perturbs that interaction, producing p53 nuclear exclusion and cell-intrinsic apoptosis. Non-senescent cells are reported to be comparatively unaffected, which is the stated basis for classifying the peptide as a senolytic.
Mechanistic descriptions summarize published in vitro and animal work. They are not a representation of efficacy or safety in any subject, and no administration guidance is given or implied.
The originating study identified FOXO4 as a pivot in senescent cell viability and reported that, under conditions where it was well tolerated in vivo, the peptide neutralized doxorubicin-induced chemotoxicity and altered fitness, fur density and renal function in fast-aging XpdTTD/TTD and naturally aged mice. In naturally aged mice, FOXO4-DRI selectively induced p53 nuclear exclusion and apoptosis in senescent Leydig cells and altered age-related testosterone secretion, with FOXO4 nuclear translocation observed in aged human Leydig cells. In human chondrocytes expanded in vitro, the peptide removed more than half of the cells at population doubling level 9 while not significantly changing cell number at the minimally expanded PDL3 control. In keloid organ cultures and fibroblasts, treatment promoted apoptosis and decreased G0/G1 phase cells alongside nuclear exclusion of p53 phosphorylated at serine 15. Countervailing data reported in Circulation found that clearing senescent cells, including with FOXO4-DRI, promoted rather than limited pulmonary hypertension development and progression in animal models, indicating that senolytic outcomes are tissue- and context-dependent. No human clinical trial of FOXO4-DRI appears in this citation set.
Sources & references
Cited literature is provided for scientific reference only and does not constitute a representation of efficacy or safety in any subject. All research findings presented are sourced from peer-reviewed journals and are provided for educational reference only.
- 01The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI
Bourgeois B, et al. · Nat Commun, 2025
- 02
- 03
- 04Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes
Huang Y, et al. · Front Bioeng Biotechnol, 2021
- 05FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice
Zhang C, et al. · Aging (Albany NY), 2020
- 06
Every entry links to its record at the publisher or on PubMed. Titles are reproduced exactly as published.
Further searches
Live database searches for FOXO4, run against the current index and retrieved independently of this site.
Bench handling, not a dosing guide.
Intended use
Supplied exclusively as a research reagent for in vitro and laboratory use by qualified researchers. Not a drug, dietary supplement, cosmetic or medical device, and not for human or veterinary use. No dosing, route or administration guidance is provided for any compound in this catalog.
Personal protection
Handle in a controlled laboratory environment with gloves and eye protection. Avoid generating or inhaling airborne particulate when opening a vial, and do not handle the material outside a designated work area.
Opening and reconstitution
Lyophilized peptides are hygroscopic. Let the sealed vial equilibrate to room temperature before opening so atmospheric moisture does not condense onto the powder. Reconstitute by directing diluent down the vial wall and swirling until dissolved — do not shake, which shears and foams the peptide.
Stability and aliquoting
Store at -20°C, protected from light. Stable 24+ months sealed. Store at 2-8°C. Use within approximately 30 days. Aliquot reconstituted material and minimize repeated freeze-thaw cycles.
Waste disposal
Dispose of unused material, reconstituted solutions and sharps through your institution's chemical and biological waste stream, in accordance with local regulations. Do not dispose of research material in domestic waste or to drain.
Others in longevity & cellular
Epithalon
Synthetic tetrapeptide Ala-Glu-Asp-Gly.
Glutathione
Reduced L-glutathione tripeptide.
Humanin
24-residue mitochondrial-derived peptide.
NAD+
Nicotinamide adenine dinucleotide, oxidized.
Important research notice
Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
This material is supplied exclusively as a research reagent for in vitro and laboratory use by qualified researchers. It is not a drug, dietary supplement, cosmetic, or medical device, is not intended for human or veterinary use, and is not intended to diagnose, treat, cure, or prevent any disease. No dosing, administration, therapeutic, or benefit claims are made or implied. Cited literature is provided for scientific reference only and does not constitute a representation of efficacy or safety in any subject.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.